Videos

John O. Mascarenhas, MD, discusses the need to develop curative therapies in myelofibrosis.  



Dr. Mascarenhas on the Need to Develop Curative Therapies in Myelofibrosis 

Articles

Joshua Richter, MD, discusses the importance of optimizing these novel therapies to make way for precision medicine in multiple myeloma.

Novel Triplet Combos Offer Deep Remissions in Relapsed/Refractory Multiple Myeloma

John O. Mascarenhas, MD, discusses the potential role of pacritinib in myeloproliferative neoplasms.  



Dr. Mascarenhas on the Potential Role of Pacritinib in MPNs 

Shambavi Richard, MD, discusses the benefit of adding daratumumab to lenalidomide and dexamethasone in patients with newly diagnosed multiple myeloma.

Dr. Richard on the Benefit of Adding Daratumumab to Standard-of-Care Rd in Myeloma

Ajai Chari, MD, discusses the approval of belantamab mafodotin-blmf in ​relapsed/refractory multiple myeloma. 








Dr. Chari on the FDA Approval of Belantamab Mafodotin in R/R Multiple Myeloma  

Joshua Richter, MD, discusses the importance of optimizing available therapies in multiple myeloma. 

The Tisch Cancer Institute

Latest from The Tisch Cancer Institute

New content coming soon, please check back later.